The current recommendation of Sell for Evolent Health Inc (NYSE:EVH) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. EVH has maintained this ranking for the last month.
EVH is one of 25 companies within the Health Care Technology GICS industry group, which is in turn part of the 783 company GICS Health Care sector. EVH has a market value of $1.1 billion which is in the top half of its industry group The stock's current Portfolio Grader ranking places it 21 among the 25 companies in this industry group, a spot that is well below-average.
Portfolio Grader currently ranks the Health Care sector number 8 among the 12 sectors in its universe putting it in the third quartile of all the GICS sectors. The Health Care Technology industry group is ranked 38 among the 69 industry groups within the GICS sectors, placing it below-average in terms of the Navellier scoring system.
The scores EVH has achieved are average or below-average scores in 6 of the 8 fundamental metrics used by Portfolio Grader in the ranking of company stocks.
The company's operational scores provide mixed results with a ranking for sales growth that is well above the industry average but rankings for operating margin and earnings growth are below average. Scores for visibility of earnings are mixed, with rankings for earnings surprises and earnings revisions that are worse than average, while the score for earnings momentum is much better than average. EVH's metrics for return on equity and cash flow are worse than its industry group average. Evolent Health's fundamental scores give EVH a place in the third quartile of the industry group.
The Navellier Proprietary Quantitative Score is used by Portfolio Grader to view EVH's shares from the perspective of risk/reward. This unique scoring system takes into account the relative value of EVH's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Considering this risk/reward calculation, the company currently scores well below-average in its industry group compared to its peers.
Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'. Explore the tool here.
Commentary provided by UpTick Data Technologies.